Rethinking Alzheimer’s: New Evidence Challenges a Long-Held Belief About Memory Loss

A new study reveals connections between two widely used models of the disease, with findings that may reshape how scientists approach treatment. If there is one fact about Alzheimer’s disease that ...
Ophthalmology Times

Q&A: The ARCHER trial and the importance of continued GA research

ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA.
Business Wire

Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to ...
sciencex

Monoclonal antibody spots complement system proteins activated on damaged tissues rather than in the bloodstream

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
News Medical

Granzyme K identified as key trigger of complement system in autoimmune diseases

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...